Masahiro Sakagami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3059575/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacokinetic profile analyses for inhaled drugs in humans using the lung delivery and disposition model. Biopharmaceutics and Drug Disposition, 2020, 41, 32-43.	1.1	3
2	In vitro, ex vivo and in vivo methods of lung absorption for inhaled drugs. Advanced Drug Delivery Reviews, 2020, 161-162, 63-74.	6.6	38
3	In Vivo-Relevant Transwell Dish-Based Dissolution Testing for Orally Inhaled Corticosteroid Products. Pharmaceutical Research, 2019, 36, 95.	1.7	10
4	In vitro lung epithelial cell transport and anti-interleukin-8 releasing activity of liposomal ciprofloxacin. European Journal of Pharmaceutical Sciences, 2018, 115, 68-76.	1.9	4
5	Salvianolic acid B as an anti-emphysema agent I: In vitro stimulation of lung cell proliferation and migration, and protection against lung cell death, and in vivo lung STAT3 activation and VEGF elevation. Pulmonary Pharmacology and Therapeutics, 2018, 53, 107-115.	1.1	8
6	Salvianolic acid B as an anti-emphysema agent II: In vivo reversal activities in two rat models of emphysema. Pulmonary Pharmacology and Therapeutics, 2018, 53, 52-60.	1.1	4
7	Sulfated dehydropolymer of caffeic acid: InÂvitro anti-lung cell death activity and inÂvivo intervention in emphysema induced by VEGF receptor blockade. Pulmonary Pharmacology and Therapeutics, 2017, 45, 181-190.	1.1	9
8	Development and characterization of a naturally derived lung extracellular matrix hydrogel. Journal of Biomedical Materials Research - Part A, 2016, 104, 1922-1935.	2.1	121
9	Pulmonary delivery of anorectic oxyntomodulin in rats: food intake suppression, reduced body weight gain and pharmacokinetics. Therapeutic Delivery, 2015, 6, 297-306.	1.2	2
10	lloprost reverses established fibrosis in experimental right ventricular failure. European Respiratory Journal, 2015, 45, 449-462.	3.1	68
11	Sulfated Caffeic Acid Dehydropolymer Attenuates Elastase and Cigarette Smoke Extract–induced Emphysema in Rats: Sustained Activity and a Need of Pulmonary Delivery. Lung, 2014, 192, 481-492.	1.4	10
12	Novel low molecular weight lignins as potential anti-emphysema agents: InÂvitro triple inhibitory activity against elastase, oxidation andÂinflammation. Pulmonary Pharmacology and Therapeutics, 2013, 26, 296-304.	1.1	32
13	Systemic delivery of biotherapeutics through the lung: opportunities and challenges for improved lung absorption. Therapeutic Delivery, 2013, 4, 1511-1525.	1.2	18
14	Targeted Drug Delivery Through the Respiratory System: Molecular Control on Lung Absorption and Disposition. , 2011, , 127-141.		4
15	In Vitro Aqueous Fluid-Capacity-Limited Dissolution Testing of Respirable Aerosol Drug Particles Generated from Inhaler Products. Pharmaceutical Research, 2010, 27, 786-795.	1.7	71
16	The Particle has Landed—Characterizing the Fate of Inhaled Pharmaceuticals. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, S-71-S-87.	0.7	191
17	Insulin Self-association: Effects on Lung Disposition Kinetics in the Airways of the Isolated Perfused Rat Lung (IPRL). Pharmaceutical Research, 2007, 24, 1636-1644.	1.7	14
18	In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Advanced Drug Delivery Reviews, 2006, 58, 1030-1060.	6.6	294

#	Article	IF	CITATIONS
19	Expression and Transport Functionality of FcRn within Rat Alveolar Epithelium: A Study in Primary Cell Culture and in the Isolated Perfused Lung. Pharmaceutical Research, 2006, 23, 270-279.	1.7	61
20	The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: Implications of metabolism and regional deposition. European Journal of Pharmaceutical Sciences, 2005, 25, 369-378.	1.9	36
21	Respirable Microspheres for Inhalation. Clinical Pharmacokinetics, 2005, 44, 263-277.	1.6	30
22	Insulin Disposition in the Lung Following Oral Inhalation in Humans. Clinical Pharmacokinetics, 2004, 43, 539-552.	1.6	43
23	Fractional contribution of lung, nasal and gastrointestinal absorption to the systemic level following nose-only aerosol exposure in rats: a case study of 3.7-µm fluorescein aerosols. Archives of Toxicology, 2003, 77, 321-329.	1.9	18
24	Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation. Journal of Controlled Release, 2002, 80, 207-218.	4.8	69
25	Solute disposition in the rat lung in vivo and in vitro: Determining regional absorption kinetics in the presence of mucociliary escalator. Journal of Pharmaceutical Sciences, 2002, 91, 594-604.	1.6	27
26	Biochemical evidence for transcytotic absorption of polyaspartamide from the rat lung: Effects of temperature and metabolic inhibitors. Journal of Pharmaceutical Sciences, 2002, 91, 1958-1968.	1.6	20
27	Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. Journal of Controlled Release, 2001, 77, 117-129.	4.8	64
28	The Lung Structure Maintenance Program: Sustaining Lung Structure during Adulthood and		0

0 Implications for COPD Risk., 0,, 303-310.